睿知中国疾病研究地图
候选清单0

正在招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由深圳市人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)深圳市人民医院Shenzhen People's Hospital深圳医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05033392,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 79 岁;性别:不限

    登记记录的入选字段

  2. Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.

    入选标准第 2 条

  3. Endoscopic ultrasonography and/or enhanced CT/MRI examination confirmed at the stage of cT3/4a Nx or T2 N1-3, M0(AJCC 8th) before randomization.

    入选标准第 3 条

  4. Patients have received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 agent.

    排除标准第 4 条

    Patients with history of autoimmune disease; patients with autoimmune-related hypothyroidism receive stable doses of thyroid hormone replacement therapy Eligible to participate in this study; Type 1 diabetes patients who are controlled after receiving a stable insulin treatment plan are eligible to participate in this study;

    排除标准第 5 条

    Patients have received systemic immunostimulatory drug therapy (including but not limited to interferon or IL-2) within 4 weeks before enrollment or within 5 half-lives of the drug (whichever is shorter);

    排除标准第 6 条

  5. The Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1

    入选标准第 5 条

  6. Neutrophil count (ANC)≥1.5×l09/L

    入选标准第 7 条

    Platelet (PLT) ≥80×109/L

    入选标准第 8 条

    Hemoglobin (Hb) level ≥9.0 g/L

    入选标准第 9 条

    Total bilirubin level≤1.5×ULN

    入选标准第 10 条

    Alanine aminotransferase (ALT) level≤3×ULN

    入选标准第 11 条

    Aspartate aminotransferase (AST) level ≤3×ULN

    入选标准第 12 条

    International normalized value (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN

    入选标准第 13 条

    Serum creatinine (Cr) level ≤1.5×ULN

    入选标准第 14 条

    Creatinine clearance >50 ml/min (Calculated according to the Cockcroft-Gault formula)

    入选标准第 15 条

  7. Patients have experienced or currently have other malignancies within 5 years.

    排除标准第 3 条

    Active infections, including tuberculosis (clinical diagnosis includes clinical history, physical examination and imaging findings, and TB examination according to local medical routines), hepatitis B {known HBV surface antigen (HBsAg) positive, and HBV DNA ≥1000cps/ml}, hepatitis C or human immunodeficiency virus (HIV antibody positive).

    排除标准第 8 条

    Patients with previous or cured HBV infection (defined as hepatitis B core antibody [anti-HBc] positive and HbsAg negative) are only eligible to participate in this study when HBV DNA is negative (HBV DNA ˂1000cps/ml).

    排除标准第 9 条

    Patients with positive hepatitis C (HCV) antibodies are only eligible to participate in this study if the polymerase chain reaction shows negative HCV RNA.

    排除标准第 10 条

  8. Women who are pregnant or breastfeeding.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05033392,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 yeas and ≤79 years. The gender is not limited.
  2. Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.
  3. Endoscopic ultrasonography and/or enhanced CT/MRI examination confirmed at the stage of cT3/4a Nx or T2 N1-3, M0(AJCC 8th) before randomization.
  4. At least 15 unstained sections of formalin-fixed paraffin-embedded tumor tissue sections or fresh tumor tissues can be provided for PD-L1, TMB, tumor infiltrating T lymphocytes, MSI-H/dMMR and EBV detection.
  5. The Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1
  6. Adequate bone marrow and organ function meets the following criteria:
  7. Neutrophil count (ANC)≥1.5×l09/L
  8. Platelet (PLT) ≥80×109/L
  9. Hemoglobin (Hb) level ≥9.0 g/L
  10. Total bilirubin level≤1.5×ULN
  11. Alanine aminotransferase (ALT) level≤3×ULN
  12. Aspartate aminotransferase (AST) level ≤3×ULN
  13. International normalized value (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN
  14. Serum creatinine (Cr) level ≤1.5×ULN
  15. Creatinine clearance >50 ml/min (Calculated according to the Cockcroft-Gault formula)

排除标准:Exclusion Criteria:

  1. Patients with a history of severe hypersensitivity to other monoclonal antibodies or any component of toripalimab injection (JS001).
  2. Preoperative pathology diagnosed as squamous cell carcinoma or neuroendocrine tumor.
  3. Patients have experienced or currently have other malignancies within 5 years.
  4. Patients have received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 agent.
  5. Patients with history of autoimmune disease; patients with autoimmune-related hypothyroidism receive stable doses of thyroid hormone replacement therapy Eligible to participate in this study; Type 1 diabetes patients who are controlled after receiving a stable insulin treatment plan are eligible to participate in this study;
  6. Patients have received systemic immunostimulatory drug therapy (including but not limited to interferon or IL-2) within 4 weeks before enrollment or within 5 half-lives of the drug (whichever is shorter);
  7. Patients who have undergone allogeneic bone marrow transplantation or solid organ transplantation in the past;
  8. Active infections, including tuberculosis (clinical diagnosis includes clinical history, physical examination and imaging findings, and TB examination according to local medical routines), hepatitis B {known HBV surface antigen (HBsAg) positive, and HBV DNA ≥1000cps/ml}, hepatitis C or human immunodeficiency virus (HIV antibody positive).
  9. Patients with previous or cured HBV infection (defined as hepatitis B core antibody [anti-HBc] positive and HbsAg negative) are only eligible to participate in this study when HBV DNA is negative (HBV DNA ˂1000cps/ml).
  10. Patients with positive hepatitis C (HCV) antibodies are only eligible to participate in this study if the polymerase chain reaction shows negative HCV RNA.
  11. There is a serious neurological or mental illness, including dementia and seizures.
  12. Suffer from NCI-CTCAE ≥ Grade 2 peripheral neuropathy.
  13. Women who are pregnant or breastfeeding.
  14. Chronic bowel disease or short bowel syndrome.
  15. Those who are deficient in the enzyme dihydropyrimidine dehydrogenase (DPD).
  16. Major cardiovascular diseases, such as New York Heart Association heart disease (level II or higher), myocardial infarction within 3 months before randomization, unstable arrhythmia, or unstable angina.
  17. Patients with known coronary artery disease, congestive heart failure that does not meet the above criteria, or left ventricular ejection fraction <50% must adopt an optimized and stable medical plan determined by the treating doctor. If necessary, you can consult a cardiologist.

引自 ClinicalTrials.gov, NCT05033392, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05033392,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05033392